Since cancer cells with elevated OXPHOS metabolism can form a barrier to T cell activity, promoting T cell exhaustion and decreasing antitumor immunity [101], further studies should explore whether FASN inhibitors, by acting as bona fide OXPHOS inhibitors targeting the mitochondrial ETC, may be particularly effective as immunotherapeutic agents in OXPHOS-dependent cancer subtypes. Here, FASN is linked to cancer.